ARTICLE | Clinical News
ProstVac regulatory update
May 10, 2010 7:00 AM UTC
FDA granted Fast Track designation to Bavarian Nordic's ProstVac to treat asymptomatic or minimally symptomatic, metastatic castration-resistant prostate cancer (mCRPC). The company plans to start a P...